microRNA-99b acts as a tumor suppressor in non-small cell lung cancer by directly targeting fibroblast growth factor receptor 3

V AmbrosThe functions of animal microRNAsNature431350355200410.1038/nature0287115372042

VN KimJ-W NamGenomics of microRNATrends Genet22165173200610.1016/j.tig.2006.01.00316446010

AJ SchetterNHH HeegaardCC HarrisInflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathwaysCarcinogenesis313749201010.1093/carcin/bgp27219955394

PB KwakS IwasakiY TomariThe microRNA pathway and cancerCancer Sci10123092315201010.1111/j.1349-7006.2010.01683.x20726859

S VoliniaGA CalinC-G LiuA microRNA expression signature of human solid tumors defines cancer gene targetsProc Natl Acad Sci USA10322572261200610.1073/pnas.051056510316461460

N YanaiharaN CaplenE BowmanUnique microRNA molecular profiles in lung cancer diagnosis and prognosisCancer Cell9189198200610.1016/j.ccr.2006.01.02516530703

J-W SonY-J KimH-M ChoMicroRNA expression profiles in Korean non-small cell lungTuberc Respir Dis67413421200910.4046/trd.2009.67.5.413

AM ChengMW ByromJ SheltonLP FordAntisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosisNucleic Acids Res3312901297200510.1093/nar/gki20015741182

C-Z ChenL LiHF LodishDP BartelMicroRNAs modulate hematopoietic lineage differentiationScience3038386200410.1126/science.109190314657504

A Esquela-KerscherP TrangJF WigginsThe let-7 microRNA reduces tumor growth in mouse models of lung cancerCell Cycle7759764200810.4161/cc.7.6.583418344688

L MaJ YoungH PrabhalamiR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasisNat Cell Biol12247256201020173740

BP LewisCB BurgeDP BartelConserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targetsCell1201520200510.1016/j.cell.2004.12.03515652477

FR LamontDC TomlinsonPA CooperSD ShnyderJD ChesterMA KnowlesSmall molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivoBr J Cancer1047582201110.1038/sj.bjc.660601621119661

DM OrnitzJ XuJS ColvinReceptor specificity of the fibroblast growth factor familyJ Biol Chem2711529215297199610.1074/jbc.271.25.152928663044

EM HaugstenA WiedlochaS OlsnesJ WescheRoles of fibroblast growth factor receptors in carcinogenesisMol Cancer Res814391452201010.1158/1541-7786.MCR-10-016821047773

D HanahanRA WeinbergThe hallmarks of cancerCell1005770200010.1016/S0092-8674(00)81683-9

RJ WebsterKM GilesKJ PricePM ZhangJS MattickPJ LeedmanRegulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7J Biol Chem28457315741200910.1074/jbc.M80428020019073608

WC ChoAS ChowJS AuMiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1RNA Biol8125131201110.4161/rna.8.1.14259

M GarofaloG Di LevaG RomanomiR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulationCancer Cell164985092009

MW NasserJ DattaG NuovoDown-regulation of micro-RNA-1 (miR-1) in lung cancerJ Biol Chem2833339433405200818818206

C BillereyD ChopinM-H Aubriot-LortonFrequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumorsAm J Pathol15819551959200110.1016/S0002-9440(10)64665-211395371

D CappellenC De OliveiraD RicolFrequent activating mutations of FGFR3 in human bladder and cervix carcinomasNat Genet231820199910.1038/1261510471491

S KangS DongT-L GuFGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathwayCancer Cell12201214200710.1016/j.ccr.2007.08.00317785202

L ChengS ZhangDD DavidsonMolecular determinants of tumor recurrence in the urinary bladderFuture Oncol5843857200910.2217/fon.09.5019663734

M ChesiE NardiniLA BrentsFrequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3Nat Genet16260264199710.1038/ng0797-2609207791

DC TomlinsonO BaldoP HarndenMA KnowlesFGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancerJ Pathol2139198200710.1002/path.220717668422

M KarouiH Hofmann-RadvanyiU ZimmermannNo evidence of somatic FGFR3 mutation in various types of carcinomaOncogene2050595061200110.1038/sj.onc.120465111526491

M WoenckhausJ MerkR StoehrPrognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancerHum Pathol39126136200810.1016/j.humpath.2007.05.02717949785

S ThomsonF PettiI Sujka-KwokD EpsteinJ HaleyKinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancyClin Exp Metastasis25843854200810.1007/s10585-008-9200-418696232

L MarekKE WareA FritzscheFibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cellsMol Pharmacol75196207200910.1124/mol.108.04954418849352

SA KonoME MarshallKE WareLE HeasleyThe fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancerDrug Resist Updat1295102200910.1016/j.drup.2009.05.00119501013

M IwatsukiK MimoriT YokoboriEpithelial-mesenchymal transition in cancer development and its clinical significanceCancer Sci101293299201010.1111/j.1349-7006.2009.01419.x19961486